Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12115-12128

  Kong, Rui ^a,b,c   Li, Hui ^b   Georgiev, Ivelin ^c   Changela, Anita ^c   Bibollet Ruche, Frederic ^b   Decker, Julie M ^a   Rowland Jones, Sarah L ^d   Jaye, Assan ^e   Guan, Yongjun ^f   Lewis, George K ^f   Langedijk, Johannes P M ^g,i   Hahn, Beatrice H ^b   Kwong, Peter D ^c   Robinson, James E ^h   Shawb, George M ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g Pepscan Therapeutics   (Netherlands)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN MONOCLONAL ANTIBODY; SOLUBLE CD4 ANTIGEN;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIOTINYLATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-2; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEUTRALIZATION TESTS; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84869111491     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01632-12     Document Type: Article

References (85)

1. Bell CH, et al. 2008. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol.Biol. 375:969-978.
2. Binley JM, et al. 1996. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retroviruses 12:911-924.
3. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
4. Bohne-Lang A, von der Lieth CW. 2005. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res. 33:W214-W219.
5. Calarese DA, et al. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U. S. A. 102:13372-13377.
6. Calarese DA, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
7. Cardoso RM, et al. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
8. Chen B, et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
9. Chen L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127
10. Chen L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127
11. Cole KS, et al. 2001. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 290:59-73.
12. Davis KL, et al. 2009. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1V3-specific antibodies in human plasma. J. Virol. 83:1240-1259.
13. Davis KL, et al. 2009. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414-426
14. Decker JM, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
15. de Silva TI, et al. 2012. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J. Virol. 86:930-946.
16. Doria-Rose NA, et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199.
17. Gao F, et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441
18. Gnanakaran S, et al. 2010. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 6:e1000955. doi:10.1371/journal.pcbi.1000955
19. Gray ES, et al. 2009. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 83:11265-11274.
20. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937
21. Guan Y, et al. 2009. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 106:3952-3957
22. Guillon C, et al. 1998. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J. Virol. 72:6260-6263.
23. Guyader M, et al. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669.
24. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis:scientific and public health implications. Science 287:607-614.
25. Hu G, Liu J, Taylor KA, Roux KH. 2011. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J. Virol. 85:2741-2750.
26. Huang CC, et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
27. Javaherian K, et al. 1994. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J.Virol. 68:2624-2631.
28. Jiang X, et al. 2010. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 17:955-961.
29. Karwowska S, et al. 1992. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8:1099-1106
30. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
31. Kong R, et al. 2012. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J. Virol. 86:947-960.
32. Kwong PD, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
33. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect.Biol. 1:a007278. doi:10.1101/cshperspect.a007278.
34. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10:573-578.
35. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
36. Langedijk JP, Meloen RH, Taylor G, Furze JM, van Oirschot JT. 1997. Antigenic structure of the central conserved region of protein G of bovine respiratory syncytial virus. J. Virol. 71:4055-4061.
37. Letvin NL, et al. 2011. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med.3:81ra36.
38. Li Y, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
39. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008.Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113.
40. McClure MO, et al. 1987. HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature 330:487-489.
41. Moore JP, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.J. Virol. 70:1863-1872.
42. Morner A, et al. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
43. Musiani M, Gallinella G, Venturoli S, Zerbini M. 2007. Competitive PCR-ELISA protocols for the quantitative and the standardized detection of viral genomes. Nat. Protoc. 2:2511-2519.
44. Muster T, et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
45. Ozkaya Sahin G, et al. 2012. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J. Virol. 86:961-971.
46. Palker TJ, et al. 1987. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc. Natl. Acad. Sci. U. S. A. 84:2479-2483
47. Pancera M, et al. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171.
48. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
49. Pinter A. 2007. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr. HIV Res. 5:542-553.
50. Reeves JD, Doms RW. 2002. Human immunodeficiency virus type 2. J.Gen. Virol. 83:1253-1265.
51. Ren X, Sodroski J, Yang X. 2005. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J. Virol. 79:5616-5624
52. Roben P, et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol.68:4821-4828.
53. Robinson JE, et al. 1998. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res. Hum. Retroviruses 14:1253-1262
54. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H. 1990.Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retroviruses 6:567-579.
55. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
56. Sato S, et al. 2008.Potent antibody-mediated neutralization and evolutionof antigenic escape variants of simian immunodeficiency virus strain SIV mac239 in vivo. J. Virol. 82:9739-9752
57. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640
58. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
59. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:439-1452
60. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb. Perspect. Med. 1:a006841. doi:10.1101/cshperspect.a006841.
61. Sol N, et al. 1997. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J.Virol. 71:8237-8244
62. Stamatatos L, Morris L, Burton DR, Mascola JR.2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
63. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA.2004.Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12:193-204
64. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA.2006. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80:6093-6105
65. Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988
66. Tiller T, et al. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.J. Immunol. Methods 329:112-124.
67. Timmerman P, Beld J, Puijk WC, Meloen RH. 2005. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. ChemBioChem 6:821-824.
68. Traggiai E, et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.Nat. Med. 10:871-875.
69. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
70. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
71. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312
72. Weiss RA, et al. 1988. HIV-2 antisera cross-neutralize HIV-1. AIDS2:95-100
73. White TA, et al. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain dependent variation in quaternary structure. PLoS Pathog.6:e1001249. doi:10.1371/journal.ppat.1001249.
74. Wu F, et al. 2012. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J.Virol. 86:8835-8847
75. Wu SR, et al. 2010. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc. Natl. Acad. Sci. U. S. A.107:18844-18849.
76. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
77. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
78. Wyatt R, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711
79. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens,antigens, and immunogens. Science 280:1884-1888
80. Yeh WW, et al. 2010. Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J. Virol. 84:6018-6032.
81. Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
82. Zhou T, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
83. Zolla-Pazner S. 2005. Improving on nature: focusing the immune response on the V3 loop. Hum. Antibodies 14:69-72.
84. Zwick MB, et al. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79:1252-1261.
85. Zwick MB, et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905